Riskpilot← Back to searchSign inGet full accessOncopeptides AB
ABActiveOrg 5565966438Luntmakargatan 46Research and experimental development on natural sciences and engineering · NACE 7210Est. 200020-49 employees
Revenue 2024
SEK 31,6M
+191% vs 2023
EBITDA margin
702.5%
+188% vs 2023
Equity ratio
69.4%
Financial strength
Net profit 2024
SEK 184,6M
+173% vs 2023
| Revenue | SEK 31,6M | +191% |
| EBITDA | SEK 222,3M | +188% |
| Net profit | SEK 184,6M | +173% |
| Total assets | SEK 760,2M | +243% |
| Equity | SEK 527,5M | +777% |
| Employees | — | — |
Legal name
Oncopeptides AB
Org number
5565966438
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5 september 2000
Share capital
SEK 23 910 000
Employees
20-49
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas två i förening av Bergentoft, Eric Henrik Heigis, Sofia Elin Elisabeth Nordström, Eva Sabina Marianne Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att, direkt eller indirekt, bedriva forskning och utveckling, tillverkning, marknadsföring, försäljning och licensiering av läkemedel som kan användas för att behandla cancer eller andra cancerrelaterade sjukdomar eller tillstånd, samt att bedriva därmed förenlig verksamhet.
Address
Luntmakargatan 46
Phone
+4686152040
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 97 577 | 559 | 10 890 | 31 648 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 7 | −114 458 | −247 620 | −420 018 | −744 179 | −1 599 994 | −1 409 814 | −352 924 | −252 188 | 222 334 |
| Depreciation & amort. | −7 | −24 | — | — | — | — | — | — | — | — |
| EBIT | 0 | −114 482 | −247 620 | −420 018 | −744 179 | −1 599 994 | −1 409 814 | −352 924 | −252 188 | 222 334 |
| Net financials | 9 | 36 | — | 18 | 26 | 358 | −38 088 | 28 824 | −9 | −3 694 |
| Profit before tax | 0 | −114 446 | −247 612 | −420 008 | −744 138 | −1 599 620 | −1 428 539 | −324 799 | −253 940 | 184 577 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −114 446 | −247 612 | −420 008 | −744 138 | −1 599 620 | −1 428 539 | −324 799 | −253 940 | 184 577 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4 402 | 55 633 | 479 822 | 443 524 | 971 126 | 844 953 | 363 495 | 357 705 | 221 780 | 760 233 |
| Equity | −2 600 | 26 337 | 418 005 | 315 258 | 793 027 | 569 528 | 204 653 | 302 610 | 60 169 | 527 502 |
| Long-term debt | 0 | 0 | 1 825 | 0 | 0 | 0 | 0 | 0 | 116 996 | 126 004 |
| Short-term debt | 7 002 | 29 296 | 59 993 | 113 408 | 144 314 | 220 024 | 158 783 | 53 280 | 44 615 | 106 727 |
| Total debt | 7 002 | 29 296 | 61 818 | 113 408 | 144 314 | 220 024 | 158 783 | 53 280 | 161 611 | 232 731 |
EBITDA margin
702.5%
This company
15.8%
Market median
+4346% vs market
20152024
Equity ratio
69.4%
This company
38.2%
Market median
+82% vs market
20152024
Return on equity
35.0%
This company
18.4%
Market median
+90% vs market
20152024
Net profit margin
583.2%
This company
8.1%
Market median
+7100% vs market
20152024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20152024
Debt / equity
0.44×
This company
0.62×
Market median
+29% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KS External Signatory | External Signatory | 2020 | — | — |
SA Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
EH External Signatory | External Signatory | 2022 | — | — |
AJ Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
MJ Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
HL External Signatory | External Signatory | 2023 | — | — |
LG Chief Auditor | Chief Auditor | 2024 | — | — |
ES Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
MS Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
BS Chief Auditor | Chief Auditor | 2020 | — | — |
SE Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
AB External Signatory | External Signatory | 2022 | — | — |
AK Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2025 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oncopeptides AB (this company)
Oncopeptides SlOncopeptides SrlOncopeptides GmbhOncopeptides, IncONCOPEPTIDES SLONCOPEPTIDES, INCONCOPEPTIDES SRLONCOPEPTIDES GMBHBoard members of Oncopeptides AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karolina Susanna Vilval | External Signatory | 0 companies |
| Stig Anders Jacob Lindberg | Chief Executive Officer | 0 companies |
| Eric Henrik Bergentoft | External Signatory | 0 companies |
| Anders Jussi Martin-Löf | Chief Executive Officer | 0 companies |
| Marty John Duvall | Chief Executive Officer | 0 companies |
| Holger Lembrér | External Signatory | 0 companies |
| Lars Gustaf Kylberg | Chief Auditor | 0 companies |
| Eva Sabina Marianne Nordström | Chief Executive Officer | 0 companies |
| Monica Shaw | Chief Executive Officer | 0 companies |
| Björn Sture Bernhard Peters Ohlsson | Chief Auditor | 0 companies |
| Sofia Elin Elisabeth Heigis | Chief Executive Officer | 0 companies |
| Annika Beata Bladh Muskantor | External Signatory | 0 companies |
| Anna Kristina Svanberg | Chief Auditor | 0 companies |
| Jennifer Ann Jackson | Board of Directors | 0 companies |
| Per Anders Göte Samuelsson | Board of Directors | 0 companies |
| Cecilia Margaretha Daun Wennborg | Board of Directors | 0 companies |
| Jarl Ulf Birger Jungnelius | Board of Directors | 0 companies |
| Brian Michael Stuglik | Board of Directors | 0 companies |
| Jonas Karl Olof Brambeck | Board of Directors | 0 companies |
| Per Wold-Olsen | Chairman | 0 companies |
| Christine Elizabeth Rankin | Board of Directors | 0 companies |